NASDAQ:ADLR - Adolor Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Adolor (NASDAQ:ADLR)

Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin). In December 2011, Cubist Pharmaceuticals, Inc. acquired Adolor Corporation.

Receive ADLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ADLR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Adolor (NASDAQ:ADLR) Frequently Asked Questions

What is Adolor's stock symbol?

Adolor trades on the NASDAQ under the ticker symbol "ADLR."

Who are some of Adolor's key competitors?

Has Adolor been receiving favorable news coverage?

Headlines about ADLR stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adolor earned a daily sentiment score of 0.22 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Adolor?

Shares of ADLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Adolor?

Adolor's mailing address is 700 Pennsylvania Dr, EXTON, PA 19341-1129, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581.

MarketBeat Community Rating for Adolor (ADLR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  71
MarketBeat's community ratings are surveys of what our community members think about Adolor and other stocks. Vote "Outperform" if you believe ADLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADLR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Adolor (NASDAQ:ADLR) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/22/2016 forward)


Adolor (NASDAQ:ADLR) Earnings History and Estimates Chart

Earnings by Quarter for Adolor (NASDAQ:ADLR)

Adolor (NASDAQ ADLR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2011Q3 2011$0.16$0.19ViewN/AView Earnings Details
7/27/2011($0.20)($0.04)ViewN/AView Earnings Details
4/28/2011($0.16)($0.16)ViewN/AView Earnings Details
2/23/2011($0.10)($0.07)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.19)($0.09)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.17)($0.18)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.18)($0.21)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.20)($0.16)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.17)($0.24)ViewN/AView Earnings Details
7/29/2009Q2 2009($0.36)($0.27)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.25)($0.28)ViewN/AView Earnings Details
2/25/2009Q4 2008($0.30)($0.33)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.23)($0.29)ViewN/AView Earnings Details
8/5/2008Q2 2008$0.22$0.16ViewN/AView Earnings Details
4/28/2008Q1 2008($0.21)($0.20)ViewN/AView Earnings Details
2/29/2008Q4 2007($0.25)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Adolor (NASDAQ:ADLR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Adolor (NASDAQ ADLR) Insider Trading and Institutional Ownership History

Insider Trading History for Adolor (NASDAQ:ADLR)

Adolor (NASDAQ ADLR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


Adolor (NASDAQ ADLR) News Headlines

No headlines for this company have been tracked by

SEC Filings

Adolor (NASDAQ:ADLR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Adolor (NASDAQ:ADLR) Income Statement, Balance Sheet and Cash Flow Statement


Adolor (NASDAQ ADLR) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.